MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 68,289 Shares

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 68,289 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $20.02, for a total value of $1,367,145.78. Following the completion of the transaction, the chief executive officer owned 2,774,893 shares in the company, valued at $55,553,357.86. The trade was a 2.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Da Silva Jorge Santos also recently made the following trade(s):

• On Thursday, July 9th, Da Silva Jorge Santos sold 33,936 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.01, for a total value of $679,059.36.
• On Wednesday, July 1st, Da Silva Jorge Santos sold 47,775 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.03, for a total value of $956,933.25.

MoonLake Immunotherapeutics Price Performance

MLTX traded up $0.05 on Monday, hitting $20.41. 1,315,029 shares of the company’s stock traded hands, compared to its average volume of 1,539,808. The company’s 50 day simple moving average is $18.60 and its 200-day simple moving average is $17.26. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -5.27 and a beta of 1.04. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.07). As a group, research analysts anticipate that MoonLake Immunotherapeutics will post -3.71 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MLTX. Kestra Advisory Services LLC bought a new stake in MoonLake Immunotherapeutics in the fourth quarter worth $26,000. FNY Investment Advisers LLC bought a new position in MoonLake Immunotherapeutics during the third quarter valued at $28,000. Bank of America Corp DE lifted its position in MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after purchasing an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after buying an additional 3,166 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after buying an additional 1,069 shares in the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MLTX. Rothschild & Co Redburn upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $12.00 to $40.00 in a research report on Thursday, March 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, June 8th. Needham & Company LLC raised their price objective on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Finally, Wolfe Research raised MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and lifted their target price for the stock from $12.00 to $24.00 in a report on Monday, March 23rd. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $24.21.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.